These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 30771170)
1. Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection. Kruse N; Mollenhauer B Methods Mol Biol; 2019; 1948():59-68. PubMed ID: 30771170 [TBL] [Abstract][Full Text] [Related]
2. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid. Kruse N; Schulz-Schaeffer WJ; Schlossmacher MG; Mollenhauer B Methods; 2012 Apr; 56(4):514-8. PubMed ID: 22465793 [TBL] [Abstract][Full Text] [Related]
3. Validation of a new assay for α-synuclein detection in cerebrospinal fluid. Førland MG; Öhrfelt A; Oftedal LS; Tysnes OB; Larsen JP; Blennow K; Zetterberg H; Alves G; Lange J Clin Chem Lab Med; 2017 Feb; 55(2):254-260. PubMed ID: 27474841 [TBL] [Abstract][Full Text] [Related]
4. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042 [TBL] [Abstract][Full Text] [Related]
5. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. Williams SM; Schulz P; Sierks MR Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448 [TBL] [Abstract][Full Text] [Related]
6. Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid. Kruse N; El-Agnaf OM; Mollenhauer B Bioanalysis; 2017 Apr; 9(8):621-630. PubMed ID: 28504552 [TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. Malek N; Swallow D; Grosset KA; Anichtchik O; Spillantini M; Grosset DG Acta Neurol Scand; 2014 Aug; 130(2):59-72. PubMed ID: 24702516 [TBL] [Abstract][Full Text] [Related]
8. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Simonsen AH; Kuiperij B; El-Agnaf OM; Engelborghs S; Herukka SK; Parnetti L; Rektorova I; Vanmechelen E; Kapaki E; Verbeek M; Mollenhauer B Biomark Med; 2016; 10(1):19-34. PubMed ID: 26314196 [TBL] [Abstract][Full Text] [Related]
9. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803 [TBL] [Abstract][Full Text] [Related]
11. α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease. Cao Z; Wu Y; Liu G; Jiang Y; Wang X; Wang Z; Feng T Neurosci Lett; 2019 Mar; 696():114-120. PubMed ID: 30579996 [TBL] [Abstract][Full Text] [Related]
12. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay. Kramer ML; Behrens C; Schulz-Schaeffer WJ Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794 [TBL] [Abstract][Full Text] [Related]
13. The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls. Jakowec MW; Petzinger GM; Sastry S; Donaldson DM; McCormack A; Langston JW Neurosci Lett; 1998 Aug; 253(1):13-6. PubMed ID: 9754793 [TBL] [Abstract][Full Text] [Related]
15. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984 [TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease biomarkers based on α-synuclein. Fayyad M; Salim S; Majbour N; Erskine D; Stoops E; Mollenhauer B; El-Agnaf OMA J Neurochem; 2019 Sep; 150(5):626-636. PubMed ID: 31265130 [TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein in peripheral body fluid as a biomarker for Parkinson's disease. Shu H; Zhang P; Gu L Acta Neurol Belg; 2024 Jun; 124(3):831-842. PubMed ID: 38170418 [TBL] [Abstract][Full Text] [Related]
18. Alpha-Synuclein as a Biomarker for Parkinson's Disease. Atik A; Stewart T; Zhang J Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058 [TBL] [Abstract][Full Text] [Related]
19. Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels. Horvath I; Iashchishyn IA; Forsgren L; Morozova-Roche LA ACS Chem Neurosci; 2017 Jun; 8(6):1170-1176. PubMed ID: 28263550 [TBL] [Abstract][Full Text] [Related]
20. Brain-Biomarker Changes in Body Fluids of Patients with Parkinson's Disease. Cocco C; Manai AL; Manca E; Noli B Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]